Page last updated: 2024-11-03

protoporphyrin ix and Skin Neoplasms

protoporphyrin ix has been researched along with Skin Neoplasms in 103 studies

protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.

Skin Neoplasms: Tumors or cancer of the SKIN.

Research Excerpts

ExcerptRelevanceReference
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."7.75A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
" In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)."7.75Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009)
"In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain."7.74Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed)."5.46Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma. ( Geilich, BM; Keidar, M; Wang, M; Webster, TJ, 2017)
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."3.75A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
" In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)."3.75Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009)
"In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain."3.74Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"We present the kinetics of ALA-induced protoporphyrin IX (PP) accumulation and the results of ALA PDT treatment on two patients with different stages (stage I and stage III) of mycosis fungoides (MF)-type cutaneous T-cell lymphoma (CTCL)."3.70Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. ( Haik, J; Kostenich, G; Malik, Z; Orenstein, A; Tamir, J; Trau, H; Winkler, E, 2000)
"Treatment of non-melanoma skin cancers (NMSC) with topical photodynamic therapy (PDT) is a treatment of choice for many clinicians."2.74A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. ( Ferguson, J; Lesar, A; Moseley, H, 2009)
"Protoporphyrin IX (PpIX) is an endogenous photosensitizer commonly used in photodynamic therapy."2.73Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies. ( Brandt, MG; Jordan, K; Moore, CC, 2007)
" This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported."2.73Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. ( Campbell, S; Curnow, A; Pye, A, 2008)
"A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies."2.61In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019)
"Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years."2.405-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. ( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997)
"Protoporphyrin IX (PpIX) is an endogenous photosensitizer (PS) widely used, obtained by the administration of precursors such as aminolevulinic acid and methyl aminolevulinate."1.56Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies. ( Bagnato, VS; Fortunato, TC; Pratavieira, S; Requena, MB; Russignoli, PE; Salvio, AG; Vollet-Filho, JD, 2020)
"Non-melanoma skin cancers are the most frequently occurring type of cancer worldwide."1.48An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy. ( Anayo, L; Curnow, A; Magnussen, A; Perry, A; Wood, M, 2018)
"Of the 60 patients (20 Bowen's disease, 20 SCC, and 20 BCC), malignant neoplasms could be clearly distinguished from adjacent healthy tissue under fluorescence illumination (P < 0."1.48Topical application of Photofrin ( Chang, CJ; Chiang, YF; Hsiao, YC; Lin, YT, 2018)
"With the application of CAP posttreatment, melanoma cell viability significantly decreased (80% were killed) compared to not using a light source (45% were killed) or using a UV light source (65% were killed)."1.46Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma. ( Geilich, BM; Keidar, M; Wang, M; Webster, TJ, 2017)
"Metastatic skin cancer cells SKMEL-30 were treated by 5-ALA in dark and then they were irradiated by 90-femtosecond (fs) laser with different pulse powers for different durations."1.40Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma. ( Gündoğdu, Y; Kara, R; Kars, MD; Kepceoğlu, A; Kılıç, HŞ, 2014)
"(R)L-sulforaphane (SF) is a compound that protects against erythema, but it can also induce DNA fragmentation that leads to cell death by apoptosis."1.35Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. ( Juzeniene, A; Mikolajewska, P; Moan, J, 2008)
" However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX."1.35Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. ( Ballini, JP; Dögnitz, N; Gabrecht, T; Lange, N; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2008)
"Etretinate-pretreated cells underwent apoptosis in response to ALA-based PDT."1.35Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( Akita, Y; Ishida, N; Kuhara, T; Matsumoto, Y; Nakano, A; Takeo, T; Tamada, Y; Watanabe, D; Yamashita, N; Yanagishita, T, 2009)
"Depth of treatment of skin cancers were increased in CaNa2 EDTA-treated group."1.32Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. ( Liu, HF; Xu, SZ; Zhang, CR, 2004)
"Ten basal cell carcinomas were coated with an ointment containing 10% ALA prior to excision; five served as controls."1.29Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. ( Landthaler, M; Sassy, T; Szeimies, RM, 1994)

Research

Studies (103)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.97)18.7374
1990's18 (17.48)18.2507
2000's38 (36.89)29.6817
2010's43 (41.75)24.3611
2020's3 (2.91)2.80

Authors

AuthorsStudies
McEwan, C1
Nesbitt, H1
Nicholas, D1
Kavanagh, ON1
McKenna, K1
Loan, P1
Jack, IG1
McHale, AP1
Callan, JF1
Schary, N1
Novak, B1
Kämper, L1
Yousf, A1
Lübbert, H1
McNicholas, K1
MacGregor, MN1
Gleadle, JM1
Requena, MB1
Russignoli, PE1
Vollet-Filho, JD1
Salvio, AG2
Fortunato, TC1
Pratavieira, S1
Bagnato, VS2
León, D1
Buchegger, K1
Silva, R1
Riquelme, I1
Viscarra, T1
Mora-Lagos, B1
Zanella, L1
Schafer, F1
Kurachi, C1
Roa, JC1
Ili, C1
Brebi, P1
Wang, M1
Geilich, BM1
Keidar, M1
Webster, TJ1
Holien, T1
Gederaas, OA1
Darvekar, SR1
Christensen, E1
Peng, Q3
Anayo, L1
Magnussen, A1
Perry, A2
Wood, M2
Curnow, A9
Wu, Y1
Wang, P1
Zhang, L1
Wang, B1
Wang, X1
Lin, YT1
Hsiao, YC1
Chiang, YF1
Chang, CJ1
Champeau, M1
Vignoud, S1
Mortier, L1
Mordon, S1
Larisch, P1
Verwanger, T1
Onder, K1
Krammer, B1
Fakhar-e-Alam, M1
Kishwar, S1
Willander, M1
Xie, H1
Xie, Z1
Mousavi, M1
Bendsoe, N2
Brydegaard, M1
Axelsson, J1
Andersson-Engels, S5
Salas-García, I2
Fanjul-Vélez, F2
Arce-Diego, JL2
Kars, MD1
Kara, R1
Gündoğdu, Y1
Kepceoğlu, A1
Kılıç, HŞ1
Salas-García, T1
López-Gómez, A1
Dorado-Fernández, M1
Ruiz-Martínez, J1
Rollakanti, KR1
Anand, S2
Davis, SC2
Pogue, BW2
Maytin, EV3
Kulyk, O1
Ibbotson, SH2
Moseley, H5
Valentine, RM3
Samuel, ID1
Bay, C1
Togsverd-Bo, K2
Lerche, CM2
Haedersdal, M2
El Hoshy, K1
Bosseila, M1
El Sharkawy, D1
Sobhi, R1
de Souza, AL1
Marra, K1
Gunn, J1
Samkoe, KS1
Kanick, SC1
Chapman, MS1
Hasan, T3
Lima, CA1
Goulart, VP1
Bechara, EJ1
Correa, L1
Zezell, DM1
Campbell, CL1
Brown, CTA1
Wood, K3
Inada, NM1
Cottrell, WJ2
Paquette, AD1
Keymel, KR1
Foster, TH2
Oseroff, AR3
Mikolajewska, P1
Juzeniene, A5
Moan, J10
Dögnitz, N1
Salomon, D1
Zellweger, M1
Ballini, JP1
Gabrecht, T1
Lange, N1
van den Bergh, H1
Wagnières, G1
de Haas, ER2
de Bruijn, HS4
Sterenborg, HJ3
Neumann, HA2
Robinson, DJ3
Ishida, N2
Watanabe, D2
Akita, Y2
Nakano, A2
Yamashita, N1
Kuhara, T1
Yanagishita, T1
Takeo, T1
Tamada, Y2
Matsumoto, Y2
Donnelly, RF2
McCarron, PA2
Al-Kassas, R1
Juzenas, P5
Iani, V4
Woolfson, AD2
Honari, G1
Elson, P1
Pudroma, X1
Ma, LW2
Kwitniewski, M1
Jankowski, D1
Jaskiewicz, K1
Dziadziuszko, H1
Peksa, R1
Kunikowska, D1
Graczyk, A1
Kwasny, M1
Kaliszewski, M1
Glosnicka, R1
Lesar, A1
Ferguson, J1
Wang, KK1
Mitra, S1
Mizutani, K1
Akimoto, M1
Torchia, D1
Cappugi, P1
Liutkeviciūte-Navickiene, J1
Mordas, A1
Simkute, S1
Bloznelyte-Plesniene, L1
Tyrrell, J3
Campbell, S4
Kosaka, S1
Kawana, S1
Lee, CY1
Kim, KH1
Kim, YH1
Ohgari, Y1
Miyata, Y1
Chau, TT1
Kitajima, S1
Adachi, Y1
Taketani, S1
Ortega-Quijano, N1
Campbell, SM2
Milla, LN1
Cogno, IS1
Rodríguez, ME1
Sanz-Rodríguez, F1
Zamarrón, A1
Gilaberte, Y1
Carrasco, E1
Rivarola, VA1
Juarranz, A1
Brown, CT2
Ibbotson, S1
Tyrrell, JS1
Morton, C1
Harms, FA1
de Boon, WM1
Balestra, GM1
Bodmer, SI1
Johannes, T1
Stolker, RJ1
Mik, EG1
van der Beek, N1
de Leeuw, J1
Demmendal, C1
Bjerring, P1
Liu, B1
Farrell, TJ1
Patterson, MS1
Philipsen, PA1
Poulsen, T1
Wulf, HC2
Wiegell, SR1
Fabricius, S1
Heydenreich, J1
Enk, CD1
Rosso, S1
Bäumler, W2
Baldursson, BT1
Gaál, M1
Kui, R1
Hunyadi, Z1
Kemény, L1
Gyulai, R1
Blake, E2
Allen, J2
Thorn, C1
Shore, A1
Kantere, D1
Guldbrand, S1
Paoli, J1
Goksör, M1
Hanstorp, D1
Wennberg, AM2
Smedh, M1
Ericson, MB1
Mathew, J1
Helliwell, P1
Sharfaei, S2
Bissonnette, R2
Diagaradjane, P1
Madhuri, S1
Aruna, P1
Gupta, PK1
Ganesan, S1
Stakland, S1
Bhasin, G1
Kausar, H1
Athar, M1
Choudry, K1
Brooke, RC1
Farrar, W1
Rhodes, LE1
Liu, HF1
Xu, SZ1
Zhang, CR1
Calin, MA1
Gruia, Ml1
Herascu, N1
Coman, T1
Ackermann, G1
Abels, C2
Szeimies, RM3
Shen, SC1
Lee, WR1
Fang, YP2
Hu, CH1
Fang, JY1
Thompson, MS1
Svanberg, S4
Johansson, T1
Palsson, S1
Derjabo, A1
Kapostins, J1
Stenram, U1
Spigulis, J1
Svanberg, K4
Gilmore, BF1
Morrow, DI1
Murphy, DJ1
Silva, JN1
Filipe, P1
Morlière, P1
Mazière, JC1
Freitas, JP1
Cirne de Castro, JL1
Santus, R1
Star, WM4
van't Veen, AJ1
Munte, K1
Smits, T1
Kleinpenning, MM1
Blokx, WA1
van de Kerkhof, PC1
van Erp, PE1
Gerritsen, MJ1
Brandt, MG1
Moore, CC1
Jordan, K1
Pye, A1
Tsai, YH1
Wu, PC1
Huang, YB1
Lee, JB1
Choi, JY1
Chun, JS1
Yun, SJ1
Lee, SC1
Oh, J1
Park, HR1
Roberts, DJ1
Cairnduff, F1
Rittenhouse-Diakun, K1
Van Leengoed, H1
Morgan, J1
Hryhorenko, E1
Paszkiewicz, G1
Whitaker, JE1
Iinuma, S1
Farshi, SS1
Ortel, B1
Sassy, T1
Landthaler, M1
Martin, A2
Tope, WD2
Grevelink, JM1
Starr, JC1
Fewkes, JL1
Flotte, TJ1
Deutsch, TF1
Anderson, RR2
van der Veen, N2
Berg, RJ1
Svaasand, LO1
Wyss, P1
Wyss, MT1
Tadir, Y1
Tromberg, BJ1
Berns, MW1
Heyerdahl, H1
Wang, I3
Liu, DL1
Berg, R1
Warloe, T1
Berg, K2
Kongshaug, M1
Giercksky, KE1
Nesland, JM1
Marcus, SL1
Sobel, RS1
Golub, AL1
Carroll, RL1
Lundahl, S1
Shulman, DG1
Ross, EV1
Kollias, N1
Gillies, R1
Stringer, MR1
Brown, SB1
Gudmundson, F1
Stenquist, B1
Ternesten, A1
Mölne, L1
Rosén, A1
Larko, O1
Langer, S1
Botzlar, A1
Pahernik, S1
Rick, K1
Goetz, AE1
af Klinteberg, C2
Enejder, AM1
Gadmar, OB1
Ma, L1
Lucroy, MD1
Edwards, BF1
Peavy, GM1
Krasieva, TB1
Griffey, SM1
Stiles, JB1
Madewell, BR1
Canti, G1
Cubeddu, R1
Eker, C1
Pifferi, A1
Taroni, P1
Valentini, G1
De Rosa, FS1
Marchetti, JM1
Thomazini, JA1
Tedesco, AC1
Bentley, MV1
Orenstein, A1
Haik, J1
Tamir, J1
Winkler, E1
Trau, H1
Malik, Z1
Kostenich, G1
van den Akker, JT1
Beijersbergen van Henegouwen, GM1
Fischer, F1
Dickson, EF1
Kennedy, JC2
Pottier, RH2
Casas, A1
Perotti, C1
Fukuda, H1
Rogers, L1
Butler, AR1
Batlle, A1
Pross, DC1
Mathews-Roth, MM1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy[NCT03167762]18 participants (Actual)Interventional2017-06-22Completed
Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737]43 participants (Actual)Interventional2019-11-01Completed
Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570]218 participants (Anticipated)Observational2022-12-01Enrolling by invitation
Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ[NCT03025724]40 participants (Anticipated)Interventional2017-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for protoporphyrin ix and Skin Neoplasms

ArticleYear
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
    British journal of cancer, 2019, Volume: 121, Issue:8

    Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat

2019
Photodynamic therapy for skin cancer: How to enhance drug penetration?
    Journal of photochemistry and photobiology. B, Biology, 2019, Volume: 197

    Topics: Aminolevulinic Acid; Drug Compounding; Humans; Liposomes; Micelles; Nanoparticles; Photochemotherapy

2019
Daylight photodynamic therapy.
    Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:8

    Topics: Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Meteorological Concepts; Photochemotherapy; Photo

2015
[Fluorescence diagnosis of non-melanoma skin cancer].
    Orvosi hetilap, 2012, Aug-26, Volume: 153, Issue:34

    Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous

2012
[Fluorescence diagnosis in dermatology].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:7

    Topics: Aminolevulinic Acid; Image Processing, Computer-Assisted; Optical Imaging; Protoporphyrins; Skin Dis

2003
Photodynamic therapies: principles and present medical applications.
    Bio-medical materials and engineering, 2006, Volume: 16, Issue:4 Suppl

    Topics: Aminolevulinic Acid; Bowen's Disease; Clinical Trials as Topic; Humans; Light; Lipoproteins, LDL; Ma

2006
Photodynamic therapy of primary skin cancer: a review.
    British journal of plastic surgery, 1995, Volume: 48, Issue:6

    Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Female; Fo

1995
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.
    Cancer, 1997, Jun-15, Volume: 79, Issue:12

    Topics: Aminolevulinic Acid; Forecasting; Heme; Humans; Neoplasms; Photochemotherapy; Protoporphyrins; Resea

1997
Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status.
    Journal of clinical laser medicine & surgery, 1996, Volume: 14, Issue:2

    Topics: Aminolevulinic Acid; Animals; Endometrium; Female; Gastrointestinal Neoplasms; Humans; Laser Therapy

1996
Beta-carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases.
    Biochimie, 1986, Volume: 68, Issue:6

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Adolescent; Adult; Animals; Bacteria; Bacterial Physiological Phen

1986

Trials

21 trials available for protoporphyrin ix and Skin Neoplasms

ArticleYear
Enhancement of Photodynamic Therapy for Bowen's Disease Using Plum-Blossom Needling to Augment Drug Delivery.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2018, Volume: 44, Issue:12

    Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Drug Delivery Systems; Female; Fluorescence; Humans; Mal

2018
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4

    Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Optical Imaging; Photosensit

2015
A quantitative study of in vivo protoporphyrin IX fluorescence build up during occlusive treatment phases.
    Photodiagnosis and photodynamic therapy, 2017, Volume: 18

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Bandages; Female; Humans; Male; Metabolic C

2017
A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin.
    Photodermatology, photoimmunology & photomedicine, 2009, Volume: 25, Issue:4

    Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middl

2009
Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
    Photodiagnosis and photodynamic therapy, 2010, Volume: 7, Issue:4

    Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Male; Photobleaching; Photochemotherap

2010
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
    The British journal of dermatology, 2011, Volume: 164, Issue:6

    Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo

2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
    The British journal of dermatology, 2011, Volume: 164, Issue:6

    Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo

2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
    The British journal of dermatology, 2011, Volume: 164, Issue:6

    Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo

2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.
    The British journal of dermatology, 2011, Volume: 164, Issue:6

    Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo

2011
PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study.
    Lasers in surgery and medicine, 2012, Volume: 44, Issue:4

    Topics: Aminolevulinic Acid; Biomarkers, Tumor; Bowen's Disease; Carcinoma; Carcinoma, Basal Cell; False Neg

2012
Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.
    Lasers in medical science, 2013, Volume: 28, Issue:3

    Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Oxygen; Pho

2013
The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.
    Journal of photochemistry and photobiology. B, Biology, 2012, Dec-05, Volume: 117

    Topics: Aminolevulinic Acid; Biological Transport; Carcinoma, Basal Cell; Injections; Oxygen; Photosensitizi

2012
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
    The British journal of dermatology, 2003, Volume: 149, Issue:1

    Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car

2003
Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.
    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2006, Volume: 25, Issue:1-2

    Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; Lasers; Male;

2006
Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up.
    Acta dermato-venereologica, 2006, Volume: 86, Issue:5

    Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; M

2006
Randomized control trial of fluorescence-guided surgical excision of nonmelanotic cutaneous malignancies.
    The Journal of otolaryngology, 2007, Volume: 36, Issue:3

    Topics: Aged; Female; Fluorescence; Humans; Male; Photosensitizing Agents; Prospective Studies; Protoporphyr

2007
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:8

    Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vi

2008
Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.
    Archives of dermatological research, 1995, Volume: 287, Issue:7

    Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male;

1995
Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid.
    Photochemistry and photobiology, 1998, Volume: 67, Issue:2

    Topics: Administration, Oral; Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Interactions; Fluorescence; H

1998
In vivo detection of basal cell carcinoma using imaging spectroscopy.
    Acta dermato-venereologica, 1999, Volume: 79, Issue:1

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Ce

1999
Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas.
    Journal of photochemistry and photobiology. B, Biology, 1999, Volume: 49, Issue:2-3

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;

1999
Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin.
    Lasers in surgery and medicine, 2000, Volume: 26, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photosensi

2000
A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy.
    Journal of controlled release : official journal of the Controlled Release Society, 2000, Apr-03, Volume: 65, Issue:3

    Topics: Aminolevulinic Acid; Animals; Dimethyl Sulfoxide; Humans; Mice; Mice, Hairless; Microscopy, Confocal

2000
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience.
    Journal of photochemistry and photobiology. B, Biology, 1990, Volume: 6, Issue:1-2

    Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Ph

1990

Other Studies

72 other studies available for protoporphyrin ix and Skin Neoplasms

ArticleYear
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: Aminolevulinic Acid; Animals; Heterografts; Humans; Melanoma; Mice, SCID; Photochemotherapy; Skin Ne

2016
Identification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell lines.
    Photodiagnosis and photodynamic therapy, 2022, Volume: 39

    Topics: Aminolevulinic Acid; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor;

2022
Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies.
    Photodiagnosis and photodynamic therapy, 2020, Volume: 29

    Topics: Aminolevulinic Acid; Animals; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents

2020
Epigallocatechin Gallate Enhances MAL-PDT Cytotoxic Effect on PDT-Resistant Skin Cancer Squamous Cells.
    International journal of molecular sciences, 2020, May-08, Volume: 21, Issue:9

    Topics: Aminolevulinic Acid; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Catechin; Cell Death; Cell H

2020
Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma.
    International journal of nanomedicine, 2017, Volume: 12

    Topics: Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Melanoma; Nanoparticles; Photochemotherapy;

2017
Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
    Lasers in surgery and medicine, 2018, Volume: 50, Issue:5

    Topics: Aminolevulinic Acid; Cell Culture Techniques; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutan

2018
An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
    Lasers in surgery and medicine, 2018, Volume: 50, Issue:5

    Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Epithelial Cells; Fibroblasts; Humans; Iron Chela

2018
Topical application of Photofrin
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2018, Volume: 71, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Bowen's Disease; Carcinoma, Basal Cell; Dihematoporphyrin Ether; Fem

2018
Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
    Photodiagnosis and photodynamic therapy, 2019, Volume: 25

    Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Humans; Iron Chelating Agents; Photochemothera

2019
In vitro analysis of photosensitizer accumulation for assessment of applicability of fluorescence diagnosis of squamous cell carcinoma of epidermolysis bullosa patients.
    BioMed research international, 2013, Volume: 2013

    Topics: Anthracenes; Carcinoma, Squamous Cell; Cell Line, Tumor; Epidermolysis Bullosa; False Positive React

2013
Photodynamic effects of zinc oxide nanowires in skin cancer and fibroblast.
    Lasers in medical science, 2014, Volume: 29, Issue:3

    Topics: Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fibroblasts; Humans; Male; Melanoma; Nanowir

2014
Design and validation of a fiber optic point probe instrument for therapy guidance and monitoring.
    Journal of biomedical optics, 2014, Volume: 19, Issue:7

    Topics: Aminolevulinic Acid; Animals; Calibration; Carcinoma, Squamous Cell; Equipment Design; Fiber Optic T

2014
Superficial radially resolved fluorescence and 3D photochemical time-dependent model for photodynamic therapy.
    Optics letters, 2014, Apr-01, Volume: 39, Issue:7

    Topics: Carcinoma, Basal Cell; Humans; Models, Biological; Photochemical Processes; Photochemotherapy; Photo

2014
Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:5

    Topics: Aged; Aminolevulinic Acid; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescence; Human

2014
Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX Production.
    Photochemistry and photobiology, 2015, Volume: 91, Issue:6

    Topics: Animals; Carcinoma, Squamous Cell; Fluorescence; Gene Expression Regulation, Neoplastic; Mice; Optic

2015
Skin tumor development after UV irradiation and photodynamic therapy is unaffected by short-term pretreatment with 5-fluorouracil, imiquimod and calcipotriol. An experimental hairless mouse study.
    Journal of photochemistry and photobiology. B, Biology, 2016, Volume: 154

    Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Calcitriol; Carcinoma, Squamous Cell; Female; Fluorou

2016
Can basal cell carcinoma lateral border be determined by fluorescence diagnosis?: Verification by Mohs micrographic surgery.
    Photodiagnosis and photodynamic therapy, 2016, Volume: 14

    Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Diagnostic Techniques, Surgical; Female; Fl

2016
Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.
    British journal of cancer, 2016, 09-27, Volume: 115, Issue:7

    Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Deferoxamine; Dose Fractio

2016
Optimization and therapeutic effects of PDT mediated by ALA and MAL in the treatment of cutaneous malignant lesions: A comparative study.
    Journal of biophotonics, 2016, Volume: 9, Issue:11-12

    Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Female; Mice; Photochemotherapy; Photosensit

2016
Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-15, Volume: 14, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Huma

2008
Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy.
    Translational research : the journal of laboratory and clinical medicine, 2008, Volume: 152, Issue:3

    Topics: Aminolevulinic Acid; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Scree

2008
Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma.
    Journal of photochemistry and photobiology. B, Biology, 2008, Dec-11, Volume: 93, Issue:3

    Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationship, Dru

2008
Microscopic distribution of protoporphyrin (PpIX) fluorescence in superficial basal cell carcinoma during light-fractionated aminolaevulinic acid photodynamic therapy.
    Acta dermato-venereologica, 2008, Volume: 88, Issue:6

    Topics: Aminolevulinic Acid; Biopsy; Carcinoma, Basal Cell; Humans; Immunohistochemistry; Ki-67 Antigen; Mic

2008
Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:3

    Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Squamous Cell; Cell Death; Dose-Response Relationship, Dr

2009
Influence of formulation factors on PpIX production and photodynamic action of novel ALA-loaded microparticles.
    Biopharmaceutics & drug disposition, 2009, Volume: 30, Issue:2

    Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Female; Gels; Mice; Mice, Inbred BALB C; Mi

2009
Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Antimetabolites, Antineoplastic; Blo

2009
A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin.
    Experimental dermatology, 2009, Volume: 18, Issue:11

    Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Hu

2009
Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin.
    International journal of cancer, 2009, Oct-01, Volume: 125, Issue:7

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Carcinogens; Carcinoma, Squamous Cel

2009
Simulations of measured photobleaching kinetics in human basal cell carcinomas suggest blood flow reductions during ALA-PDT.
    Lasers in surgery and medicine, 2009, Volume: 41, Issue:9

    Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Cardiovascular; Photobleaching; Photoche

2009
Heating increases protoporphyrin IX production in normal skin after delivery of 5-aminolevulinic acid by iontophoresis.
    Photodermatology, photoimmunology & photomedicine, 2009, Volume: 25, Issue:6

    Topics: Adult; Aminolevulinic Acid; Hot Temperature; Humans; Iontophoresis; Male; Middle Aged; Photosensitiz

2009
Intralesional photodynamic therapy: a comment on 'Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy' by Gerritsen et al.
    Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:1

    Topics: Aminolevulinic Acid; Humans; Injections, Intralesional; Photochemotherapy; Protoporphyrins; Skin Neo

2010
[Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
    Medicina (Kaunas, Lithuania), 2009, Volume: 45, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell

2009
Validation of a non-invasive fluorescence imaging system to monitor dermatological PDT.
    Photodiagnosis and photodynamic therapy, 2010, Volume: 7, Issue:2

    Topics: Aged; Aminolevulinic Acid; Dose-Response Relationship, Drug; Fluorescence; Humans; Keratosis, Actini

2010
A case of Bowen's disease successfully treated by photodynamic therapy.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2010, Volume: 77, Issue:3

    Topics: Aminolevulinic Acid; Bowen's Disease; Female; Humans; Middle Aged; Photochemotherapy; Photosensitizi

2010
The efficacy of photodynamic diagnosis in defining the lateral border between a tumor and a tumor-free area during Mohs micrographic surgery.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010, Volume: 36, Issue:11

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carci

2010
Quinolone compounds enhance delta-aminolevulinic acid-induced accumulation of protoporphyrin IX and photosensitivity of tumour cells.
    Journal of biochemistry, 2011, Volume: 149, Issue:2

    Topics: Aminolevulinic Acid; Drug Synergism; Female; Ferric Compounds; Fluoroquinolones; HeLa Cells; Heme Ox

2011
Photodynamic effects on basal cell carcinoma with topical Photosensitizer.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2010, Volume: 2010

    Topics: Administration, Topical; Carcinoma, Basal Cell; Dermatology; Humans; Monte Carlo Method; Necrosis; O

2010
Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
    Photodiagnosis and photodynamic therapy, 2011, Volume: 8, Issue:1

    Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Drug Combinations; Female; Humans; Male; Metabolic Cle

2011
Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy.
    Journal of cellular biochemistry, 2011, Volume: 112, Issue:9

    Topics: Aminolevulinic Acid; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion Molecules; Cel

2011
Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas.
    Journal of biomedical optics, 2011, Volume: 16, Issue:4

    Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Models, Biological; Monte Carlo Method; Phantoms

2011
Oxygen-dependent delayed fluorescence measured in skin after topical application of 5-aminolevulinic acid.
    Journal of biophotonics, 2011, Volume: 4, Issue:10

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Fluorescence; Male; Oxygen; Photosensitizing

2011
Comparison of noninvasive photodynamic therapy dosimetry methods using a dynamic model of ALA-PDT of human skin.
    Physics in medicine and biology, 2012, Feb-07, Volume: 57, Issue:3

    Topics: Aminolevulinic Acid; Computer Simulation; Humans; Models, Statistical; Optics and Photonics; Oxygen

2012
Porphyrin biodistribution in UV-exposed murine skin after methyl- and hexyl-aminolevulinate incubation.
    Experimental dermatology, 2012, Volume: 21, Issue:4

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Availability; Female; Humans; Mice

2012
Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations.
    The British journal of dermatology, 2013, Volume: 168, Issue:1

    Topics: Aminolevulinic Acid; Dose-Response Relationship, Radiation; Europe; Geography, Medical; Humans; Isra

2013
Anti-Stokes fluorescence from endogenously formed protoporphyrin IX--implications for clinical multiphoton diagnostics.
    Journal of biophotonics, 2013, Volume: 6, Issue:5

    Topics: Humans; Infrared Rays; Lasers; Microscopy, Fluorescence, Multiphoton; Molecular Imaging; Protoporphy

2013
Modelling fluorescence in clinical photodynamic therapy.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2013, Volume: 12, Issue:1

    Topics: Aminolevulinic Acid; Humans; Models, Theoretical; Monte Carlo Method; Photobleaching; Photochemother

2013
Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice.
    Archives of dermatological research, 2002, Volume: 294, Issue:5

    Topics: Administration, Cutaneous; Aminolevulinic Acid; Animals; Drug Administration Schedule; Mice; Mice, H

2002
In vivo pharmacokinetics of 8-aminolevulinic acid-induced protoporphyrin IX during pre- and post-photodynamic therapy in 7,12-dimethylbenz(a)nthracene-treated skin carcinogenesis in Swiss mice: a comparison by three-compartment model.
    Photochemistry and photobiology, 2002, Volume: 76, Issue:1

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Carcinogens; Female; Mice; Models, B

2002
Photosensitizing effect of protoporphyrin IX in pigmented melanoma of mice.
    Biochemical and biophysical research communications, 2002, Sep-27, Volume: 297, Issue:3

    Topics: Administration, Topical; Alamethicin; Aminolevulinic Acid; Animals; Cell Division; Hutchinson's Mela

2002
Protoporphyrin-IX accumulation and cutaneous tumor regression in mice using a ferrochelatase inhibitor.
    Cancer letters, 2002, Dec-10, Volume: 187, Issue:1-2

    Topics: Animals; Enzyme Inhibitors; Female; Ferrochelatase; Light; Mice; Organometallic Compounds; Photochem

2002
Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy.
    Chinese medical journal, 2004, Volume: 117, Issue:6

    Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Edetic Acid; Female; Humans; Male; Middle Aged

2004
The monitoring of the accumulation of protoporphyrin IX in Walker tumours by subcutaneous administration of delta-aminolevulinic acid.
    Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:3

    Topics: Aminolevulinic Acid; Animals; Carcinoma 256, Walker; Injections, Subcutaneous; Photochemotherapy; Ph

2004
In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser.
    Journal of pharmaceutical sciences, 2006, Volume: 95, Issue:4

    Topics: Administration, Cutaneous; Aluminum; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Cell Line,

2006
In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2006, Volume: 63, Issue:3

    Topics: Aminolevulinic Acid; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, High Pressure Liqu

2006
Fluorescence diagnosis in keratinocytic intraepidermal neoplasias.
    Journal of the American Academy of Dermatology, 2007, Volume: 57, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Squamous Cell; Cell Proliferation; D

2007
Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy.
    International journal of pharmaceutics, 2008, May-22, Volume: 356, Issue:1-2

    Topics: Aminolevulinic Acid; Animals; Chemistry, Pharmaceutical; Drug Stability; Drug Storage; Ethanol; Fema

2008
Relationship of protoporphyrin IX synthesis to photodynamic effects by 5-aminolaevulinic acid and its esters on various cell lines derived from the skin.
    The British journal of dermatology, 2008, Volume: 159, Issue:1

    Topics: Aminolevulinic Acid; Cell Death; Cell Line; Dose-Response Relationship, Drug; Esters; Flow Cytometry

2008
The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA).
    Photochemistry and photobiology, 1995, Volume: 61, Issue:5

    Topics: Aminolevulinic Acid; Cells, Cultured; Heme; Humans; Lymphocyte Activation; Lymphocytes; Mitogens; Ph

1995
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
    British journal of cancer, 1994, Volume: 70, Issue:1

    Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division;

1994
Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma.
    Photochemistry and photobiology, 1994, Volume: 59, Issue:1

    Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Microscopy, Fluorescenc

1994
Kinetics and localisation of PpIX fluorescence after topical and systemic ALA application, observed in skin and skin tumours of UVB-treated mice.
    British journal of cancer, 1996, Volume: 73, Issue:7

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Female; Injections,

1996
Dosimetry model for photodynamic therapy with topically administered photosensitizers.
    Lasers in surgery and medicine, 1996, Volume: 18, Issue:2

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Transport, Active; Dogs; Models, B

1996
Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues.
    Cancer letters, 1997, Jan-30, Volume: 112, Issue:2

    Topics: Adenocarcinoma; Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Drug Interactions; Humans; Live

1997
Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin.
    Photochemistry and photobiology, 1999, Volume: 69, Issue:1

    Topics: Aminolevulinic Acid; Animals; Female; Fluorescence; Male; Mice; Mice, Hairless; Neoplasms, Radiation

1999
Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine.
    The Journal of investigative dermatology, 1999, Volume: 112, Issue:5

    Topics: Aminolevulinic Acid; Animals; Biological Transport; Cricetinae; Deferoxamine; Diffusion Chambers, Cu

1999
The temperature dependence of protoporphyrin IX production in cells and tissues.
    Photochemistry and photobiology, 1999, Volume: 70, Issue:4

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Cell Line; Cricetinae; Female; Humans; Mice;

1999
Preclinical study in cats of the pro-photosensitizer 5-aminolevulinic acid.
    American journal of veterinary research, 1999, Volume: 60, Issue:11

    Topics: Aminolevulinic Acid; Animals; Biotransformation; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell

1999
Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2000, Volume: 26, Issue:8

    Topics: Abdomen; Administration, Topical; Adult; Aged; Aminolevulinic Acid; Facial Dermatoses; Humans; Lymph

2000
Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB-induced early skin cancer.
    Photochemistry and photobiology, 2000, Volume: 72, Issue:3

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Fluorescence; Mice; Mice, Hairless; Neoplasms

2000
An affordable, portable fluorescence imaging device for skin lesion detection using a dual wavelength approach for image contrast enhancement and aminolaevulinic acid-induced protoporphyrin IX. Part II. In vivo testing.
    Lasers in medical science, 2001, Volume: 16, Issue:3

    Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Female; Humans; Mice; Mice, Inbred BALB C; Phot

2001
ALA and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization.
    British journal of cancer, 2001, Nov-30, Volume: 85, Issue:11

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminolevulinic Acid; Animals; Female; Kidney; Liver; Mice; Neoplas

2001
Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester.
    Journal of photochemistry and photobiology. B, Biology, 2002, Volume: 67, Issue:1

    Topics: Administration, Topical; Aminolevulinic Acid; Animals; Female; Fluorescence; Kinetics; Mice; Mice, H

2002